(XERS) Xeris Pharmaceuticals - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US98422E1038
Stock: Glucagon, Periodic Paralysis, Cushings Syndrome, Hypothyroidism
Total Rating 51
Risk 36
Buy Signal -1.10
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 63.9% |
| Relative Tail Risk | -22.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.30 |
| Alpha | 76.45 |
| Character TTM | |
|---|---|
| Beta | 0.906 |
| Beta Downside | 1.399 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.67% |
| CAGR/Max DD | 1.66 |
Description: XERS Xeris Pharmaceuticals January 20, 2026
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a commercial-stage biopharma focused on chronic endocrine and neurological disorders. Its marketed portfolio includes Gvoke® (stable, ready-to-use glucagon for severe hypoglycemia), Keveyis™ (treatment for primary periodic paralysis variants), and Recorlev™ (cortisol synthesis inhibitor for Cushing’s syndrome). The company’s pipeline features XP-8121, a once-weekly subcutaneous levothyroxine currently in Phase 3 for hypothyroidism.
As of the latest 10-K, Xeris reported approximately $71 million of total revenue in FY 2023, driven primarily by Gvoke sales, and held $158 million in cash and marketable securities, giving it ~12 months of runway at its current burn rate. The glucagon rescue market is projected to grow ~6 % CAGR through 2028, while the Cushing’s-syndrome niche (~$1 billion) remains under-served, positioning Recorlev for potential market share gains pending FDA approval. Xeris’s upcoming regulatory milestones include a PDUFA date for Keveyis in Q3 2024 and a Phase 3 readout for XP-8121 expected late 2024.
For a deeper, data-driven view of XERS’s valuation dynamics, you might find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -15.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 15.77 > 1.0 |
| NWC/Revenue: 40.51% < 20% (prev 38.31%; Δ 2.20% < -1%) |
| CFO/TA 0.03 > 3% & CFO 10.6m > Net Income -15.6m |
| Net Debt (-53.4m) to EBITDA (26.6m): -2.01 < 3 |
| Current Ratio: 1.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.6m) vs 12m ago 19.21% < -2% |
| Gross Margin: 83.54% > 18% (prev 0.78%; Δ 8275 % > 0.5%) |
| Asset Turnover: 77.00% > 50% (prev 58.35%; Δ 18.65% > 0%) |
| Interest Coverage Ratio: 0.47 > 6 (EBITDA TTM 26.6m / Interest Expense TTM 29.6m) |
Altman Z'' -5.76
| A: 0.29 (Total Current Assets 224.0m - Total Current Liabilities 116.2m) / Total Assets 370.2m |
| B: -1.84 (Retained Earnings -682.4m / Total Assets 370.2m) |
| C: 0.04 (EBIT TTM 14.0m / Avg Total Assets 345.6m) |
| D: -1.84 (Book Value of Equity -682.4m / Total Liabilities 371.1m) |
| Altman-Z'' Score: -5.76 = D |
Beneish M -3.04
| DSRI: 0.92 (Receivables 53.8m/41.1m, Revenue 266.1m/187.4m) |
| GMI: 0.94 (GM 83.54% / 78.47%) |
| AQI: 0.79 (AQ_t 0.32 / AQ_t-1 0.40) |
| SGI: 1.42 (Revenue 266.1m / 187.4m) |
| TATA: -0.07 (NI -15.6m - CFO 10.6m) / TA 370.2m) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of XERS shares?
As of February 09, 2026, the stock is trading at USD 7.01 with a total of 948,348 shares traded.
Over the past week, the price has changed by -4.76%, over one month by -13.78%, over three months by -9.20% and over the past year by +96.36%.
Over the past week, the price has changed by -4.76%, over one month by -13.78%, over three months by -9.20% and over the past year by +96.36%.
Is XERS a buy, sell or hold?
Xeris Pharmaceuticals has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy XERS.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the XERS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.1 | 58.9% |
| Analysts Target Price | 11.1 | 58.9% |
| ValueRay Target Price | 10 | 43.1% |
XERS Fundamental Data Overview February 05, 2026
P/E Forward = 66.6667
P/S = 4.5762
P/B = 3.3354
Revenue TTM = 266.1m USD
EBIT TTM = 14.0m USD
EBITDA TTM = 26.6m USD
Long Term Debt = 219.5m USD (from longTermDebt, last quarter)
Short Term Debt = 6.19m USD (from shortTermDebt, last quarter)
Debt = 38.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.16b USD (1.22b + Debt 38.2m - CCE 91.6m)
Interest Coverage Ratio = 0.47 (Ebit TTM 14.0m / Interest Expense TTM 29.6m)
EV/FCF = 58.74x (Enterprise Value 1.16b / FCF TTM 19.8m)
FCF Yield = 1.70% (FCF TTM 19.8m / Enterprise Value 1.16b)
FCF Margin = 7.45% (FCF TTM 19.8m / Revenue TTM 266.1m)
Net Margin = -5.88% (Net Income TTM -15.6m / Revenue TTM 266.1m)
Gross Margin = 83.54% ((Revenue TTM 266.1m - Cost of Revenue TTM 43.8m) / Revenue TTM)
Gross Margin QoQ = 85.22% (prev 79.58%)
Tobins Q-Ratio = 3.15 (Enterprise Value 1.16b / Total Assets 370.2m)
Interest Expense / Debt = 19.03% (Interest Expense 7.27m / Debt 38.2m)
Taxrate = 0.0% (0.0 / 621.0k)
NOPAT = 14.0m (EBIT 14.0m * (1 - 0.00%))
Current Ratio = 1.93 (Total Current Assets 224.0m / Total Current Liabilities 116.2m)
Debt / Equity = -44.35 (negative equity) (Debt 38.2m / totalStockholderEquity, last quarter -861.0k)
Debt / EBITDA = -2.01 (Net Debt -53.4m / EBITDA 26.6m)
Debt / FCF = -2.69 (Net Debt -53.4m / FCF TTM 19.8m)
Total Stockholder Equity = -21.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.52% (Net Income -15.6m / Total Assets 370.2m)
RoE = 73.68% (negative equity) (Net Income TTM -15.6m / Total Stockholder Equity -21.2m)
RoCE = 7.06% (EBIT 14.0m / Capital Employed (Equity -21.2m + L.T.Debt 219.5m))
RoIC = 6.87% (NOPAT 14.0m / Invested Capital 203.8m)
WACC = 9.55% (E(1.22b)/V(1.26b) * Re(9.25%) + D(38.2m)/V(1.26b) * Rd(19.03%) * (1-Tc(0.0)))
Discount Rate = 9.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.40%
[DCF Debug] Terminal Value 63.56% ; FCFF base≈19.8m ; Y1≈13.0m ; Y5≈5.94m
Fair Price DCF = 0.87 (EV 91.7m - Net Debt -53.4m = Equity 145.1m / Shares 165.9m; r=9.55% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 90.04 | EPS CAGR: 138.4% | SUE: -1.70 | # QB: 0
Revenue Correlation: 97.69 | Revenue CAGR: 38.94% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.31 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+399.2% | Growth Revenue=+26.0%
P/S = 4.5762
P/B = 3.3354
Revenue TTM = 266.1m USD
EBIT TTM = 14.0m USD
EBITDA TTM = 26.6m USD
Long Term Debt = 219.5m USD (from longTermDebt, last quarter)
Short Term Debt = 6.19m USD (from shortTermDebt, last quarter)
Debt = 38.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.16b USD (1.22b + Debt 38.2m - CCE 91.6m)
Interest Coverage Ratio = 0.47 (Ebit TTM 14.0m / Interest Expense TTM 29.6m)
EV/FCF = 58.74x (Enterprise Value 1.16b / FCF TTM 19.8m)
FCF Yield = 1.70% (FCF TTM 19.8m / Enterprise Value 1.16b)
FCF Margin = 7.45% (FCF TTM 19.8m / Revenue TTM 266.1m)
Net Margin = -5.88% (Net Income TTM -15.6m / Revenue TTM 266.1m)
Gross Margin = 83.54% ((Revenue TTM 266.1m - Cost of Revenue TTM 43.8m) / Revenue TTM)
Gross Margin QoQ = 85.22% (prev 79.58%)
Tobins Q-Ratio = 3.15 (Enterprise Value 1.16b / Total Assets 370.2m)
Interest Expense / Debt = 19.03% (Interest Expense 7.27m / Debt 38.2m)
Taxrate = 0.0% (0.0 / 621.0k)
NOPAT = 14.0m (EBIT 14.0m * (1 - 0.00%))
Current Ratio = 1.93 (Total Current Assets 224.0m / Total Current Liabilities 116.2m)
Debt / Equity = -44.35 (negative equity) (Debt 38.2m / totalStockholderEquity, last quarter -861.0k)
Debt / EBITDA = -2.01 (Net Debt -53.4m / EBITDA 26.6m)
Debt / FCF = -2.69 (Net Debt -53.4m / FCF TTM 19.8m)
Total Stockholder Equity = -21.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.52% (Net Income -15.6m / Total Assets 370.2m)
RoE = 73.68% (negative equity) (Net Income TTM -15.6m / Total Stockholder Equity -21.2m)
RoCE = 7.06% (EBIT 14.0m / Capital Employed (Equity -21.2m + L.T.Debt 219.5m))
RoIC = 6.87% (NOPAT 14.0m / Invested Capital 203.8m)
WACC = 9.55% (E(1.22b)/V(1.26b) * Re(9.25%) + D(38.2m)/V(1.26b) * Rd(19.03%) * (1-Tc(0.0)))
Discount Rate = 9.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.40%
[DCF Debug] Terminal Value 63.56% ; FCFF base≈19.8m ; Y1≈13.0m ; Y5≈5.94m
Fair Price DCF = 0.87 (EV 91.7m - Net Debt -53.4m = Equity 145.1m / Shares 165.9m; r=9.55% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 90.04 | EPS CAGR: 138.4% | SUE: -1.70 | # QB: 0
Revenue Correlation: 97.69 | Revenue CAGR: 38.94% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.31 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+399.2% | Growth Revenue=+26.0%